Immune therapy for cancer is being pursued with extraordinary interest by investigators and pharma industries, given the new scientific acquisitions on immune mechanisms that control cancer.The paradigm for immune therapy of cancer is allogeneic stem cell transplantation, whose therapeutic effect is carried out by immunocompetent T cells of the donor, an effect known as graftversus- leukemia or graft-versus-tumor effect (GVT).Thirty eight Centers who had transplanted 63 patients were contacted. Eighteen (47%) agreed to contribute data, for a total of 32 patients (51%).In conclusion, allograft for solid tumors as adoptive immunotherapy is still being used in EBMT Centers, in a few centers and in a few selected indications. Centers are willing to share data, adopt common protocols and continue to use this strategy in highly selected cases.

Bregni M., Badoglio M., Pedrazzoli P., Lanza F. (2016). Is allogeneic transplant for solid tumors still alive?. BONE MARROW TRANSPLANTATION, 51(5), 751-752 [10.1038/bmt.2015.345].

Is allogeneic transplant for solid tumors still alive?

Lanza F.
Ultimo
Project Administration
2016

Abstract

Immune therapy for cancer is being pursued with extraordinary interest by investigators and pharma industries, given the new scientific acquisitions on immune mechanisms that control cancer.The paradigm for immune therapy of cancer is allogeneic stem cell transplantation, whose therapeutic effect is carried out by immunocompetent T cells of the donor, an effect known as graftversus- leukemia or graft-versus-tumor effect (GVT).Thirty eight Centers who had transplanted 63 patients were contacted. Eighteen (47%) agreed to contribute data, for a total of 32 patients (51%).In conclusion, allograft for solid tumors as adoptive immunotherapy is still being used in EBMT Centers, in a few centers and in a few selected indications. Centers are willing to share data, adopt common protocols and continue to use this strategy in highly selected cases.
2016
Bregni M., Badoglio M., Pedrazzoli P., Lanza F. (2016). Is allogeneic transplant for solid tumors still alive?. BONE MARROW TRANSPLANTATION, 51(5), 751-752 [10.1038/bmt.2015.345].
Bregni M.; Badoglio M.; Pedrazzoli P.; Lanza F.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/917960
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact